© 2023 Evoke Canale, An Evoke Company All Rights Reserved
A page or section that allows users to communicate with the site owners which features various information fields such as name and email but can also expand with more customized options.
Affini-T Therapeutics was founded with world-class science from the Fred Hutchinson Cancer Research Center, including the lab of Juno co-founder Dr. Phil Greenberg, to unlock the power of T-cells against solid tumors by targeting oncogenic driver mutations. The company had grown quietly with the support of its early investors, Vida Ventures and Leaps by Bayer, but it recognized a need to leave stealth mode in 2022. To elevate to the next level of growth it became essential to quickly establish a strong reputation among a broader base of investors, partners and recruits as one of the most promising biopharma companies during the year.
Evoke Canale kicked off with Affini-T to build the company’s corporate positioning and messaging. This was quickly applied to development of a presentation at the 2022 JP Morgan Healthcare Conference and a concurrent article published in STAT News. This provided a strong base that was built upon over the course of the year – with an emphasis on earned media, social media and corporate award opportunities. During that time, particular attention was paid to how the company could secure a placement on a top year-end award, such as the Endpoints 11.
The communication program was successful in helping Affini-T generate awareness of its platform, team and pipeline over the course of the year. The media relations program resulted in 44 published articles across top industry, regional and business outlets, and the social media program grew its LinkedIn to 3,000 followers with high quality content. Multiple announcements were provided as exclusives to Endpoints News, which along with formal nominations helped the company secure a place on the 2022 Endpoints 11 list.